Premium
Rational Design of Cyclopenta[2,1‐b;3,4‐b′]dithiophene‐bridged Hole Transporting Materials for Highly Efficient and Stable Perovskite Solar Cells
Author(s) -
Lin YanDuo,
Lee KunMu,
Ke BoYu,
Chen KaiShiang,
Cheng HaoChien,
Lin WeiJuih,
Chang Sheng Hsiung,
Wu ChunGuey,
Kuo MingChung,
Chung HsinCheng,
Chou ChienChun,
Chen HengYu,
Liau KangLing,
Chow Tahsin J.,
Sun ShihSheng
Publication year - 2019
Publication title -
energy technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.91
H-Index - 44
eISSN - 2194-4296
pISSN - 2194-4288
DOI - 10.1002/ente.201800939
Subject(s) - triphenylamine , materials science , energy conversion efficiency , perovskite (structure) , mesoporous material , photovoltaic system , molecule , carbazole , electrochemistry , chemical engineering , electron mobility , perovskite solar cell , planarity testing , nanotechnology , optoelectronics , crystallography , photochemistry , catalysis , electrode , chemistry , organic chemistry , ecology , engineering , biology
A series of small‐molecule‐based hole‐transporting materials (HTMs) featuring a 4 H ‐cyclopenta[2,1‐b : 3,4‐b′]dithiophene as the central core with triphenylamine‐ and carbazole‐based side groups was synthesized and evaluated for perovskite solar cells. The correlations of the chemical structure of the HTMs on the photovoltaic performance were explored through different combinations of the central π‐bridge moieties. The optical and electrochemical properties, energy levels, and hole mobility were systematically investigated, revealing the significant influence of the central core planarity and packing structure on their photovoltaic performance. The optimized device based on CT1 exhibited a PCE (power conversion efficiency) of 17.71 % with a device architecture of FTO/TiO 2 compact layer/TiO 2 mesoporous/CH 3 NH 3 PbI 3 /HTM/MoO 3 /Ag, which was found to be on par with that of a cell fabricated based on state‐of‐the‐art spiro‐OMeTAD (16.97 %) as HTM. Moreover, stability assessment showed an improved stability for CPDT‐based HTMs in comparison with spiro‐OMeTAD over 1300 h.